Skip to content

Endomicroscopy, IBS and Food Intolerance

Confocal Endomicrosopy for the Detection of Food Intolerance in Patients With Irritable Bowel Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01692613
Enrollment
60
Registered
2012-09-25
Start date
2012-09-30
Completion date
2014-09-30
Last updated
2015-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endomicroscopy, Food Intolerance, Inflammatory Bowel Syndrome

Brief summary

Background: The immediate endoscopic identification and diagnosis of intraepithelial structures and immediate and delayed reactions to allergens in the mucosal surface of the gut are unmet goals in the diagnosis and management of subjects with food intolerances, who are negative to all available tests. Endomicroscopy may be helpful to further visualize and characterize unmasked small bowel reactions to foods, which has not been described before. Confocal laser endomicroscopy provides confocal microscopic imaging simultaneously to the macroscopic view ,which enables the examiner to see immediate reactions after exposure and it further allows capturing of fluid excreted by the gut for further analysis to understand the pathology behind this reaction further. N=50 patients with unexplained bloating and diarrhoea with suspicion of food intolerance and negative testing with routine methods. Patients with Lactose intolerance n=10 patients to compare results. Patients with Fructose intolerance n=10 patients to compare results. Volunteers with Barrett's esophagus who need evaluation for possible dysplasia in the Barrett's mucosa with confocal endomicrosopy but no symptoms of bloating and abdominal pain (n=10) to serve as healthy controls for allergy testing. Methods: The primary objective is to investigate whether endomicroscopy will allow the detection of an allergic reaction of the gut after exposure of the 5 major allergens in the following way: After standard gastroscopy with the endomicroscope including evaluation of the surface of the upper gastrointestinal tract, i.v. injection of Fluorescein, then initial visualisation of the duodenal surface including count of initial lymphocytes/mononuclear cells in the lamina propria: Allergen 1 (milk), allergen 2 (wheat), allergen 3 (soya),allergen 4 (apple), allergen 5 (yeast). The primary endpoint is the visible marked increase of lymphocytes and mononuclear cells in the lamina propria of the duodenum, representing an acute reaction to one of the allergens sprayed to its surface through the endoscope channel.

Detailed description

The primary endpoint is the visible marked increase of lymphocytes and mononuclear cells in the lamina propria of the duodenum, representing an acute reaction to one of the allergens sprayed to its surface through the endoscope channel.

Interventions

None listed

Sponsors

Great Ormond Street Hospital for Children NHS Foundation Trust
CollaboratorOTHER
Johannes Gutenberg University Mainz
CollaboratorOTHER
University Hospital Schleswig-Holstein
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* age \> 18 years * ongoing abdominal symptoms such as bloating and abdominal pain * negative routine testing for food intolerance (or known lactose/fructose intolerance) * written informed consent

Exclusion criteria

* no consent * known reason for the abdominal pain and bloating other than lactose/fructose intolerance * M. Whipple * known infectious gastrointestinal disease * stricture in the upper gastrointestinal tract * age \>18years * impaired renal function (Creatinine \>1.2 mg/dL) * pregnancy or breast feeding * inability to obtain informed consent * active GI Bleeding * known allergy to Methylene blue or Fluorescein * participation in other clinical trials within the last 4 weeks

Design outcomes

Primary

MeasureTime frame
Number of mucosal reactionimmediate

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026